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Abstract
Objective: Kaolin-based activated clotting time assessed by HEMOCHRON (HkACT) is a clinical standard for heparin monitoring alone and
combinedwith aprotinin during cardiopulmonary bypass (CPB). However, aprotinin is known to prolong not only celite-based but also kaolin-based
activated clotting time. Overestimation of activated clotting times implies a potential hazardous risk of subtherapeutic heparin anticoagulation.
Recently, a novel ‘aprotinin-insensitive’ activated clotting time test has been developed for the SONOCLOT analyzer (SaiACT). The aim of our
study was to evaluate SaiACT in patients undergoing CPB in presence of heparin and aprotinin. Methods: Blood samples were taken from 44
elective cardiac surgery patients at the following measurement time points: baseline (T0); before CPB after heparinization (T1 and T2); on CPB,
before administration of aprotinin (T3); 15, 30, and 60 min on CPB after administration of aprotinin (T4, T5, and T6); after protamine infusion
(T7). On each measurement time point, activated clotting time was assessed with HkACTand SaiACT, both in duplicate. Furthermore, the rate of
factor Xa inhibition and antithrombin concentration were measured. Statistical analysis was done using Bland and Altman analysis, Pearson’s
correlation, and ANOVA with post hoc Bonferroni—Dunn correction. Results: Monitoring anticoagulation with SaiACT showed reliable readings.
Compared to the established HkACT, SaiACT values were lower at all measurement time points. On CPB but before administration of aprotinin
(T3), SaiACT values (mean  SD) were 44  118 s lower compared to HkACT. However, the difference between the two measurement techniques
increased significantly on CPB after aprotinin administration (T4—T6; 89  152 s, P = 0.032). Correlation of ACT measurements with anti-Xa
activity was unchanged for SaiACT before and after aprotinin administration (r2 = 0.473 and 0.487, respectively; P = 0.794), but was lower for
HkACT after aprotinin administration (r2 = 0.481 and 0.361, respectively; P = 0.041). On CPB after administration of aprotinin, 96% of all ACT
values were classified as therapeutic by HkACT, but only 86% of all values were classified therapeutic if ACT was determined by SaiACT. Test
variability was comparable for SaiACTand HkACT. Conclusions: The use of SaiACT may result in more consistent heparin management that is less
affected by aprotinin and a corresponding increase in heparin administration for patients receiving aprotinin.
# 2006 Elsevier B.V. All rights reserved.
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Aprotinin has been shown to reduce postoperative
bleeding in patients after cardiopulmonary bypass (CPB)
[1]. Measurement of activated clotting time (ACT) is a
standard monitoring procedure for guiding heparin-induced
anticoagulation. Depending on the coagulation activator§ This work has been presented in part at the annual meeting of the
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American Society of Anesthesiologists in Atlanta, GA, October 2005.
* Corresponding author. Tel.: +41 44 466 2209; fax: +41 44 466 2743.
E-mail address: Christoph.hofer@triemli.stzh.ch (C.K. Hofer).
1010-7940/$ — see front matter # 2006 Elsevier B.V. All rights reserved.
doi:10.1016/j.ejcts.2006.05.016used, ACT measurements may be prolonged to various
degrees in the presence of aprotinin. Overestimation of
activated clotting times implies a potential hazardous risk of
subtherapeutic heparin anticoagulation and must be
avoided. When routine doses of heparin and aprotinin are
applied for CPB, kaolin-based ACT is considered to be a
standard test to guide heparin management because kaolin-
based ACT is less affected than celite-based ACT [2,3].
However, kaolin-based ACT has also been shown to be
prolonged significantly in the presence of aprotinin [3,4].
Recently, a new ACT test, SaiACT (SonoclotW Coagulation
& Platelet Function Analyzer, Sienco Inc., Arvada, CO, USA),
has been developed for the SONOCLOTanalyzer, with specific
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unaffected by the presence of aprotinin. This novel test is
labeled ‘aprotinin-insensitive’ by the manufacturer (SONO-
CLOT’s aprotinin-insensitive ACT, SaiACT). The cuvette is
manufactured with a blend of celite to initiate blood
coagulation and a type of clay to neutralize aprotinin. Like
other ACT machines, the SONOCLOT analyzer also incorpo-
rates a mechanical means to detect a fibrin clot. A resonant
mechanical oscillator responds to viscoelastic changes that
occur during clot formation. After adding a blood sample to
the SaiACT cuvette and mixing the sample with the mineral
reagents, the change in impedance to movement imposed by
the developing clot is measured and an activated clotting
time determined.
We have previously evaluated this new SaiACT technology
in vitro in presence of clinically relevant concentrations of
heparin, aprotinin, and hemodilution [5]. Addition of
aprotinin to heparinized blood samples induced no significant
changes of SaiACT measurements. By contrast, ACT values
measured with an established kaolin-based ACT from
HEMOCHRON (HkACT; HemochronW 801, International Tech-
nidyne Corp., Edison, NJ, USA) increased significantly in
heparinized samples if aprotinin was present, and in vitro
hemodilution pronounced this effect.
The aim of the present study was to evaluate this new
SaiACT from SONOCLOT in vivo in patients undergoing CPB in
the presence of heparin and aprotinin, and to compare the
SaiACT test with an established kaolin-based ACT from
HEMOCHRON (HkACT) as well as plasma levels of heparin
measured by anti-factor Xa activity (anti-Xa).2. Materials and methods
With local ethics committee approval and patient-written
informed consent, 44 patients scheduled for elective cardiac
surgery with CPB were enrolled. Inclusion criteria were age
>18 years and one of the following surgical procedures:
aortic valve replacement (AVR), aortic aneurysm repair,
mitral valve surgery (MVS, reconstruction or replacement),
and complex procedures involving combined valve coronary
artery bypass grafting (CABG) or multiple valve procedures.
At our hospital, most CABG procedures are done without CPB
(i.e., off-pump technique); hence, these patients were not
available for inclusion in this study. Exclusion criteria were
repair of congenital heart defects, emergency procedures
and known coagulation disorders (including pharmacologi-
cally induced coagulopathies, i.e., pre-treatment with any
anticoagulants or anti-platelet drug).
Anesthesia, heparin anticoagulation, CPB, protamine
reversal, and transfusion therapy were all managed by
standardized institutional protocols. Anesthesia was induced
andmaintained with propofol and fentanyl, and pancuronium
bromide was given for neuromuscular blockade. Fluid
management was done with lactated Ringer’s solution
(Laboratory Dr. Bichsel AG, Switzerland) and 6% hydroxy
ethyl starch solution (HES 130/0.4, VoluvenW, Fresenius Kabi,
Bad Homburg, Germany). Anticoagulation for CPB was
attained with IV porcine heparin (LiqueminW, Roche Pharma,
Switzerland) 300 U kg1. Heparin management was guided by
HkACT, and HkACT > 480 s was accepted as adequate antic-oagulation for CPB. CPB was performed with a membrane
oxygenator (Quadrox HMO1010, Maquet Cardiopulmonary
AG, Hirlingen, Germany) under moderate hypothermia (28—
32 8C) at flows between 2.2 and 2.4 l min1 m2. Ten
thousand units of heparin but no aprotinin was added to
the standard priming volume (1800 ml) of the CPB circuit.
After initiating the CPB, one bolus of aprotinin 2 Mio kIU
(TrasylolW; Bayer Pharmaceuticals Corp., Germany) was
administered directly to the CPB circuit (modified low-dose
aprotinin regimen, also called pump-prime-only regimen
[6]). To keep HkACT > 480 s, additional heparin in 5000 U
increments were administered during CPB, if necessary.
Anticoagulation was reversed after rewarming and separa-
tion from CPB with protamine up to a maximum dose of 1 mg
per 100 U of total heparin dose administered.
Blood samples were taken from an unheparinized central
venous line after removing five dead space volumes of blood
at the following measurement time points: baseline, after
induction of anesthesia but before skin incision (T0); before
CPB, 3 min after the first (200 U kg1, T1) and 3 min after the
second dose (100 U kg1, T2) of heparin; 5 min on CPB,
before administration of aprotinin 2 Mio kIU to the CBP
circuit (T3); 15, 30, and 60 min on CPB after administration of
aprotinin (T4, T5, and T6); and after protamine infusion and
re-transfusion of the remaining blood from the CPB circuit
(T7).
ACTwas measured with two different ACT analyzers each
in duplicate, the SONOCLOT analyzer with the novel
‘aprotinin-insensitive’ ACT test (SaiACT; SonoclotW Coagula-
tion & Platelet Function Analyzer, Sienco Inc.; normal range
in whole blood 62—93 s) and the HEMOCHRON analyzer with
the standard kaolin-based ACT test (HkACT; HemochronW
801, International Technidyne Corp.; normal range in whole
blood 91—151 s). For the SaiACT, 360 ml of freshly withdrawn
blood was filled into the cuvette, mixed and analyzed.
Immediately after, 2 ml of the same blood specimen was
filled into a HkACT cuvette, mixed and analyzed. The
performance of each machine was verified with recom-
mended quality control tests according to the manufac-
turers. Results were recorded as mean of duplicate
measurements for each of the devices. All measurements
were performed by the same investigator to avoid inter-
observer variability.
To measure laboratory blood coagulation, further blood
samples were withdrawn at each time point in citrated tubes
(final concentration of sodium citrate 0.109 mol l1; Vacuet-
teW 9NC, Greiner Bio-One, Austria). The samples were
immediately centrifuged (2500  g for 20 min at 4 8C), and
the supernatant (plasma) stored at 32 8C for later
measurements. Blood coagulation parameters were mea-
sured on an automated STA-RW coagulation analyzer
(Diagnostica Stago, Asnie`re, France). At each time point,
the rate of factor Xa inhibition (anti-Xa, assessment of the
heparin concentration) and antithrombin concentration (AT)
was measured. Anti-Xa activity was determined by assessing
the level of inhibition of the hydrolysis of a chromogenic
substrate (by the factor Xa) in the presence of heparin-
antithrombin complexes with the STAW-Rotachrom-Heparin
test (Diagnostica Stago). This assay is specifically designed to
reflect a directly proportional relationship between the rate
of factor Xa inhibition and the heparin concentration. Some
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prior to the analysis, in order to be on the linear part of the
standard curve (0.10—0.70 U ml1). AT activity was deter-
mined with the use of the chromogenic STAW-Antithrombin-III
test (Diagnostica Stago, normal range in whole blood = 80—
120%). All coagulation tests and quality controls (on normal
and abnormal levels) were performed according to the
manufacturer’s instructions.
Statistical analysis was done using StatViewW for Windows
version 5.01W (SAS Institute Inc., Cary, NC, USA) and SPSS for
Windows Release 12.0.2 (SPSS Inc., Chicago, IL, USA). Bland
and Altman analysis was done to compare SaiACTwith HkACT
[7]. Bias is defined as mean of difference (SaiACT  HkACT)
and 2 standard deviations (SD) reflect upper and lower
limits of agreement. ANOVA for repeated measures with post
hoc Bonferroni—Dunn correction and a two-sided paired
Student’s t-test were performed to compare the coagulation
parameters at different time points. Pearson’s correlations
with Fisher’s z-transformation and Hotelling Williams’ test
were used to assess the relationship between both SaiACTand
HkACT with heparin levels (anti-Xa) before and after
aprotinin administration as well as between AT and
hematocrit. Test variability of duplicate measurements
was calculated as percentage of the mean of duplicate
measurements. Unless otherwise stated, data are presented
as mean  SD. P-values <0.05 were considered statistically
significant.3. Results
A total of 333 blood samples from 44 patients were
studied. For 19 patients (43%) CPB time was 60—80 min and
thus, ACT measurements for the last measurement on CPB
(T6) were not performed. Demographic data, procedures,
and intraoperative data are summarized in Table 1. ACT
measurements were done in duplicates with SaiACT (n = 666)
and HkACT (n = 666) in a wide range before, during, and after
CPB (Fig. 1A). Both ACT analyzers were user friendly and no
technical or handling problems occurred with either device
during the study period.Table 1
Demographic data, procedures, and intraoperative data
Demographic data
Age, years 65  13
Sex, M/F n = 25 (57%)/n = 19 (43%)
Euro Score 6.1  2.6
Procedures (n)
AVR 10 (23%)
AVR+ 22 (50%)
MVR 8 (18%)
MVR+ 4 (9%)
OP time, min 223  65
CPB time, min 108  31
ACC time, min 67  21
Data are presented as mean  SD. AVR, aortic valve replacement; AVR+,
AVR + coronary artery bypass graft surgery (n = 9), resection of a subaortic
stenosis (n = 6), size reduction ascending aortoplasty (n = 4), or composite
graft (n = 3); MVR, mitral valve replacement/reconstruction; MVR+,
MVR + coronary artery bypass graft surgery; OP, operation; CPB, cardiopul-
monary bypass, ACC, aortic cross clamping.
Fig. 1. Time course of SONOCLOT’s aprotinin-insensitive ACT (SaiACT) and
HEMOCHRON’s kaolin-based ACT (HkACT) (A), rate of factor Xa inhibition (anti-
Xa) and antithrombin (AT) concentration (B), and hematocrit and temperature
(C).At each time point, 44 blood samples were measured by both ACTanalyzers
with the exception of T6 (25 blood samples). Values are presented as
mean  SD. The measurement time points were: baseline, after induction
of anesthesia but before skin incision (T0); before CPB, 3 min after 1st
(200 U kg1, T1) and 3 min after second dose of heparin (100 U kg1, T2);
5 min on CPB, before administration of aprotinin 2 Mio kIU to the CBP circuit
(T3); 15, 30, and 60 min on CPB, after administration of aprotinin (T4, T5, and
T6); after protamine infusion (T7).
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Fig. 2. Bland and Altman analysis between SONOCLOT’s aprotinin-insensitive ACT (SaiACT) and HEMOCHRON’s kaolin-based ACT (HkACT) before (T0—T3; A) and after
administration of aprotinin (T4—T7; B). Bias (black line) is defined as mean of difference (SaiACT  HkACT) and 2 standard deviations (SD) reflect upper and lower
limits of agreement (broken lines). For further details on measurement time points see Fig. 1 or Section 2. Mean bias  SD: T0 = 26  11 s, T1 = 46  50 s,
T2 = 55  124 s, T3 = 44  118 s, T4 = 72  144 s, T5 = 102  165 s, T6 = 93  147 s, T7 = 18  11 s.
Table 2
Pearson’s correlation coefficients (r2) comparing SONOCLOT’s aprotinin-insen-
sitive ACT (SaiACT) and HEMOCHRON’s kaolin-based ACT (HkACT) with rate of
factor Xa inhibition (anti-Xa) before and after administration of aprotinin
SaiACT HkACT
Before aprotinin (T0—T3) anti-Xa 0.473 (P < 0.001) 0.481 (P < 0.001)
After aprotinin (T4—T7) anti-Xa 0.497 (P < 0.001) 0.361 (P < 0.001)
r2 before versus r2 after
aprotinin
P = 0.799 P = 0.041Baseline values (T0) and values after protamine adminis-
tration (T7)were 19—26% lower for SaiACTcompared toHkACT
(P < 0.001, Fig. 2). Anticoagulation with heparin (T1 and T2)
resulted in a significant, comparable increase of SaiACT,
HkACT, and anti-Xa activity (Fig. 1A and B). Initiating CPB
(hemodilution, T3) further increased SaiACT and HkACT, but
anti-Xa remained unchanged (10,000 U heparin was added to
the priming volume of the CPB circuit). AT, hematocrit, and
body temperature decreased significantly (Fig. 1B and C).
Administration of aprotinin increased the bias between SaiACT
and HkACT during CPB significantly (Figs. 1A and 2; T4—T6),
whereas anti-Xa and AT remained unchanged (Fig. 1B). There
was some correlation between ATand hematocrit throughout
the study period (r2 = 0.289, P < 0.001).
Bias between SaiACT and HkACT at each measurement
time point is shown in Fig. 2A (before aprotinin administra-
tion, T0—T3) and Fig. 2B (after aprotinin administration,
T4—T7). Overall bias before administration of aprotinin
(T0—T3) was 48  101 s and increased significantly afterinfusion of aprotinin (T4—T7) to 91  151 s (P = 0.032).
Correlation for SaiACTand HkACTwas better before (T0—T3;
r2 = 0.880) than after aprotinin administration (T4—T6;
r2 = 0.801, P < 0.001).
Correlation of ACT measurements with anti-Xa activity
(Table 2) was comparable for SaiACT and HkACT before
patients received aprotinin (T0—T3). After administration of
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SaiACT, but worsened significantly for HkACT.
Dividing measured ACT values in two groups — below and
above the therapeutic ACT target of 480 s for a safe CPB
procedure — the following results were obtained: On CPB
after administration of aprotinin (T4—T6), 96% of all values
were classified as therapeutic by HkACT, but this was only the
case in 86% of all values if ACT was determined by SaiACT.
Twenty-five percent of all studied patients experienced at
least one episode with ‘therapeutic’ ACT values (>480 s)
determined by HkACT but ‘inadequate’ ACT values (<480 s)
when determined by SaiACT.
Test variability was comparable for both ACT measure-
ment techniques: Overall test variability for SaiACT was
7.5  7.4% and for HkACT 7.8  11%. No significant differ-
ence was observed in heparinized blood samples before (T1—
T3) and after (T4—T7) aprotinin administration (SaiACT:
P = 0.438; HkACT: P = 0.087).4. Discussion
The novel ‘aprotinin-insensitive’ ACT from SONOCLOT
(SaiACT) showed lower readings at all measurement time
points in patients undergoing CPB before and after admin-
istration of aprotinin when compared to the kaolin-based ACT
from HEMOCHRON (HkACT). Bias between the two measure-
ment techniques increased significantly after aprotinin
administration. Correlation of ACT measurements with
anti-Xa activity was unchanged for SaiACT before and after
aprotinin administration, but declined significantly for
HkACT measurements after aprotinin administration. On
CPB after administration of aprotinin, 96% of all ACT values
were classified as therapeutic by HkACT, but this was only the
case in 86% of all values if ACT was determined by SaiACT.
Heparin anticoagulation is used during cardiac surgery to
prevent overt thrombosis of the extracorporeal circuit and to
minimize excessive CPB-related activation of the hemostatic
system. As there is substantial variability of heparin antic-
oagulant responsiveness, heparin administration is usually
monitored by point-of-care instruments that measure ACT.
The ACT, initially described as a manual technique by
Hattersley [8] and introduced into cardiac surgery by Bull
et al. [9] is the amount of time it takes to form a clot by
contact activation of the coagulation cascade. ACT measure-
ment may be performed using different coagulation activa-
tors like diatomaceous earth (celite), clay (kaolin), glass-
beads, or a blend of these materials. Different activators
have different characteristics and interactions, and even the
same coagulation activator manufactured by different
companies respond differently under similar conditions [3].
Results from different ACT tests cannot be used inter-
changeably. Different baseline for SaiACT has to be
accounted for when used as alternative to HkACT. In this
study, baseline SaiACT values were 19—26% lower compared
to HkACT, on average. This finding has to be considered using
SaiACT to guide anticoagulation during CPB.
Although widely used, many factors — patient, operator,
and equipment — may affect ACT measurements. The ACT is
subject to bias from various interventions that are typical
during cardiac surgery, particularly patient hypothermia[10], inadequacy of specimen warming [11], hemodilution
[11], quantitative and qualitative platelet abnormalities
[12], or aprotinin infusion [2,3]. The technique has been
criticized because of its extreme variability and the weak
correlation with plasma heparin concentrations during CPB
[13]. Our data show a strong correlation between ACT
measurements and heparin concentration before CPB.
Initiating CPB increased both ACT readings similarly but
heparin levels remained unchanged (Fig. 1A and B)
worsening the correlation between ACT measurements
and anti-Xa. Hemodilution by itself has been shown to be
responsible for the prolongation of the ACT measurements
during initiating CPB [11]. Furthermore, correlation of ACT
measurements with anti-Xa activity was unchanged for
SaiACT before and after aprotinin administration, but
declined significantly for HkACT measurements after
aprotinin administration.
The concentration of AT paralleled the course of the
hematocrit therefore reflecting at least in part the degree of
hemodilution by the CPB, as shown by Linden et al. [14]
earlier. Interestingly, despite the decrease in AT to about 50%
after initiating CPB in our study, the concentration of ATwas
still adequate for heparin to exert its potent anticoagulant
effect. It is known that AT concentrations correlate with
heparin’s effect to inhibit coagulation: lower AT levels are
associated with a decreased heparin dose response as
measured by the ACT. However, in vitro data showed that
only AT levels <30% are associated with impaired heparin
action [15].
Aprotinin has been questioned lately for its overall safety
in two large studies on patients undergoing CPB: Mangano
et al. [16] and Karkouti et al. [17] reported dose-dependent
serious renal, cardio- and cerebrovascular adverse events
after aprotinin administration in this clinical setting.
Interestingly, patients treated with aminocaproic acid or
tranexamic acid showed similar reduction in blood loss
compared to patients treated with aprotinin, but these
patients had no renal, cardio- and cerebrovascular adverse
events [16,17]. The question remains, why only aprotinin but
not the other antifibrinolytic agents caused these serious
adverse events. In both studies, patients received one of the
anti-fibrinolytic agents at physician discretion, i.e., the
studies were non-randomized. However, both studies
included large numbers of patients and statistical procedures
were used to adjust for known differences between the
treatment groups. Another possible explanation for the
adverse events seen in patients treated with aprotinin could
have been that these patients were under-heparinized during
CPB. Aprotinin is a non-specific serine protease inhibitor and
may prolong ACT measurements to various degrees depend-
ing on the coagulation activator used. This drug is known to
inhibit contact activation, preferentially celite mediated
activation in vitro [18,19]. Kaolin-based ACT is less affected
than celite-based ACT, most likely because kaolin binds
aprotinin [20] and because kaolin more potently activates
coagulation than celite [18]. However, kaolin-based ACT has
also been shown to be prolonged significantly in the presence
of aprotinin [3,4]. Overestimation of anticoagulation, i.e.,
falsely prolonged ACT implies a potential hazardous risk of
subtherapeutic heparin anticoagulation and must be avoided
during CPB. For example, in a recent investigation, Koster
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based ACT resulted in lower heparin concentrations com-
pared to a heparin concentration-based anticoagulation
management during CPB. These lower heparin concentra-
tions used in patients managed by kaolin-based ACTs were
associated with increased hemostatic activation and inflam-
matory response.
Limited data exist that define the optimal ACT for
initiation and maintenance of CPB. In a recent survey of the
Society of Cardiovascular Anesthesiology and American
Society of Extracorporeal Circulation, it was found that the
target ACT used by 82% of responders was 400—480 s or
greater, with an additional 4.5% targeting an even higher
ACT [10]. When the achievement of the usual target of
>480 s was considered, an adequate anticoagulation during
CPB after aprotinin administration, 96% of all ACT values
were classified as therapeutic by HkACT, but this was only
the case in 86% of all values if ACT was determined by
SaiACT.
Each ACT measurement was performed in duplicate for
both SaiACT and HkACT to evaluate test variability. Both
methods were comparable and showed mean test variability
between 7 and 8%. According to the manufacturers of both
analyzers, coefficient of variation should not exceed 5%
under control conditions. Nonetheless, published data on
performance of ACT devices in control plasma and whole
blood differ largely and were mostly below 10% [22,23].
Costs for the two ACT tests used in this study are
comparable at our institution: we pay approximately three
EUR for both ACT tests taking into account our current
workload (we perform 7000—10,000 ACT tests per year) and
rental agreements.
This study has some limitations. We were able to conclude
that heparin management with SaiACT may result in an
increased administration of heparin. However, we did not
answer the question if higher heparin doses in patients
treated with aprotinin are justified in terms of patient’s
outcomes. Further studies are needed, measuring coagula-
tion activation as well as recording patient’s outcome data in
heparinized patients on CPB guided by SaiACT. Furthermore,
according to our institutional protocol, our patients received
aprotinin only in a modified half-dose regimen (pump-prime-
only regimen, 2 Mio kIU in CPB circuit). For this regimen,
anticipated aprotinin serum concentrations range between
150 and 250 kIU ml1 [24]. Additionally, different volumes of
blood used to measure ACTwith the SONOCLOT (360 ml) and
the HEMOCHRON analyzer (2 ml) have to be considered. Both
measurements may be affected to a varying degree by
external conditions: Large volume ACT tests may be more
influenced by temperature and the hypocoagulability seen in
hemodiluted blood samples may depend on the sampling
volume used [25].
In conclusion, the novel ‘aprotinin-insensitive’ ACT test
measured by the SONOCLOT analyzer (SaiACT) may be a
valuable alternative to monitor heparin anticoagulation in
presence of aprotinin compared to the kaolin-based ACT
assessed by HEMOCHRON (HkACT). Values for SaiACT are
lower than values for HkACT, and administration of
aprotinin increases this difference significantly. Therefore,
the use of SaiACT may result in an increased administration
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